[Aminoguanidine and other AGE inhibitors].
Kawakami
Masanobu
M
Department of Comprehensive Medicine I, Omiya Medical Center, Jichi Medical School.
Kuroki
Masatoshi
M
D000577:Amides / Q000494:pharmacology; D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000209:etiology; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology; D002386:Cataract / Q000188:drug therapy / Q000209:etiology; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000209:etiology; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000209:etiology; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000209:etiology; D004195:Disease Models, Animal; D015195:Drug Design; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors*; D006146:Guanidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013830:Thiadiazoles / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use; D053778:Thiazolidines
D000577:Amides; D017127:Glycation End Products, Advanced; D006146:Guanidines; D006834:Hydrazines; D007004:Hypoglycemic Agents; C105739:OPB 9195; D013830:Thiadiazoles; D013844:Thiazoles; D053778:Thiazolidines; C406794:alagebrium; C468887:ALT-946; C004479:pimagedine